Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion

J Natl Cancer Inst. 1992 Jun 17;84(12):972-4. doi: 10.1093/jnci/84.12.972.

Authors

Y Ohe¹, Y Sasaki, T Shinkai, K Eguchi, T Tamura, A Kojima, H Kunikane, H Okamoto, A Karato, H Ohmatsu, et al.

Affiliation

¹ Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.

PMID: 1321253
DOI: 10.1093/jnci/84.12.972

No abstract available

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Agents, Phytogenic / administration & dosage*
Antineoplastic Agents, Phytogenic / adverse effects
Antineoplastic Agents, Phytogenic / pharmacokinetics*
Camptothecin / administration & dosage
Camptothecin / adverse effects
Camptothecin / analogs & derivatives*
Camptothecin / pharmacokinetics
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / metabolism
Colonic Neoplasms / drug therapy*
Colonic Neoplasms / metabolism
Diarrhea / chemically induced
Drug Evaluation
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / metabolism
Humans
Irinotecan
Leukopenia / chemically induced
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
Middle Aged
Pharyngeal Neoplasms / drug therapy*
Pharyngeal Neoplasms / metabolism

Substances

Antineoplastic Agents, Phytogenic
Irinotecan
Camptothecin